Recruitment Retention & Diversity: The Evolution Of Patient Engagement In Clinical Trials
Recruitment Retention & Diversity: The Evolution Of Patient Engagement In Clinical Trials
Sponsored by:
Sponsored by:
More from Clinical Trials
• By
The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.
• By
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
• By
Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
More from R&D
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Sponsored by:
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.
Sponsored by:
Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.